H. Mario Geysen

H. Mario Geysen, Ph.D., is a distinguished scientist in SRI Biosciences. Geysen joined SRI’s Center for Advanced Drug Research (CADRE) in Shenandoah Valley, Virginia in 2010. In this role, Geysen expands SRI's research capabilities into diseases such as diabetes and osteoporosis. He is also establishing programs to develop novel molecules that control hormonal regulation in metabolic diseases.

Geysen is a pioneer in the field of combinatorial chemistry, often described as the intersection of chemistry, robotics, instrumentation, computer science, and engineering. It is recognized that combinatorial chemistry has dramatically altered and accelerated the pace of pharmaceutical discovery and development. Several new therapies are currently under development that will help provide needed medicines to patients.

Prior to joining SRI, Geysen was the Alfred Burger Professor of Chemistry at the University of Virginia (now emeritus). Prior to that, he was a distinguished scientist at GlaxoSmithKline. His career includes experience in government, industry, and academia. He has founded several successful biotechnology firms, such as Mimotopes, and has developed many innovative technologies for pharmaceutical drug discovery.

Geysen has received numerous awards in the U.S. and internationally and has more than 125 publications and patents. He holds advanced degrees in chemistry and microbiology from the University of Melbourne, Australia, and in chemical engineering from University College, London (U.K.).